BRPI1013618A2 - pirimidinas substituídas para o tratamento de câncer - Google Patents
pirimidinas substituídas para o tratamento de câncerInfo
- Publication number
- BRPI1013618A2 BRPI1013618A2 BRPI1013618A BRPI1013618A BRPI1013618A2 BR PI1013618 A2 BRPI1013618 A2 BR PI1013618A2 BR PI1013618 A BRPI1013618 A BR PI1013618A BR PI1013618 A BRPI1013618 A BR PI1013618A BR PI1013618 A2 BRPI1013618 A2 BR PI1013618A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer treatment
- substituted pyrimidines
- pyrimidines
- substituted
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155515 | 2009-03-18 | ||
| EP10153211 | 2010-02-10 | ||
| PCT/EP2010/053451 WO2010106097A1 (en) | 2009-03-18 | 2010-03-17 | Substituted pyrimidines for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013618A2 true BRPI1013618A2 (pt) | 2016-04-19 |
Family
ID=42111169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013618A BRPI1013618A2 (pt) | 2009-03-18 | 2010-03-17 | pirimidinas substituídas para o tratamento de câncer |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20110071158A1 (pt) |
| EP (1) | EP2408752B1 (pt) |
| JP (1) | JP5628281B2 (pt) |
| KR (1) | KR20110128927A (pt) |
| CN (1) | CN102421762A (pt) |
| AR (1) | AR076134A1 (pt) |
| AU (1) | AU2010224881A1 (pt) |
| BR (1) | BRPI1013618A2 (pt) |
| CA (1) | CA2755759A1 (pt) |
| CL (1) | CL2011002300A1 (pt) |
| EA (1) | EA201101330A1 (pt) |
| IL (1) | IL214746A0 (pt) |
| MX (1) | MX2011009780A (pt) |
| TW (1) | TW201043611A (pt) |
| UY (1) | UY32494A (pt) |
| WO (1) | WO2010106097A1 (pt) |
| ZA (1) | ZA201105986B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008152195A (ru) * | 2006-06-15 | 2010-07-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа |
| MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2493560A1 (en) * | 2009-10-30 | 2012-09-05 | Cardiac Pacemakers, Inc. | Pacemaker with vagal surge monitoring and response |
| ES2577829T3 (es) * | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| NO2638031T3 (pt) | 2010-11-10 | 2018-03-10 | ||
| US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
| US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| ES2648226T3 (es) * | 2012-11-08 | 2017-12-29 | Bristol-Myers Squibb Company | Compuestos de pirimidina sustituidos con alquilamida útiles en la modulación de IL-12, IL-23 y/o IFN |
| MX2015009952A (es) * | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
| CN106146468B (zh) * | 2015-04-17 | 2020-12-01 | 杭州雷索药业有限公司 | 吡啶酮类蛋白激酶抑制剂 |
| CN106478700B (zh) * | 2015-08-26 | 2020-12-29 | 杭州雷索药业有限公司 | 硼基取代的苯胺类蛋白激酶抑制剂 |
| KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| EP3994132A1 (en) | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| UY38994A (es) | 2019-12-20 | 2021-07-30 | Nuevolution As | Compuestos activos frente a receptores nucleares |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE342892T1 (de) * | 1998-08-29 | 2006-11-15 | Astrazeneca Ab | Pyrimidine verbindungen |
| SK287270B6 (sk) * | 1998-11-10 | 2010-05-07 | Janssen Pharmaceutica N. V. | Derivát pyrimidínu |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| BR0209774A (pt) * | 2001-05-29 | 2004-06-01 | Schering Ag | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento |
| ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| EP1470121B1 (en) * | 2002-01-23 | 2012-07-11 | Bayer HealthCare LLC | Pyrimidine derivatives as rho-kinase inhibitors |
| ES2273047T3 (es) * | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
| ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| US7754714B2 (en) * | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| US7521457B2 (en) * | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2634646C (en) * | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| PE20120006A1 (es) * | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| ES2555803T3 (es) * | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
-
2010
- 2010-03-15 US US12/723,782 patent/US20110071158A1/en not_active Abandoned
- 2010-03-16 UY UY0001032494A patent/UY32494A/es not_active Application Discontinuation
- 2010-03-17 CA CA2755759A patent/CA2755759A1/en not_active Abandoned
- 2010-03-17 WO PCT/EP2010/053451 patent/WO2010106097A1/en not_active Ceased
- 2010-03-17 CN CN2010800203078A patent/CN102421762A/zh active Pending
- 2010-03-17 AR ARP100100853A patent/AR076134A1/es unknown
- 2010-03-17 TW TW099107870A patent/TW201043611A/zh unknown
- 2010-03-17 JP JP2012500237A patent/JP5628281B2/ja active Active
- 2010-03-17 AU AU2010224881A patent/AU2010224881A1/en not_active Abandoned
- 2010-03-17 KR KR1020117024196A patent/KR20110128927A/ko not_active Withdrawn
- 2010-03-17 EA EA201101330A patent/EA201101330A1/ru unknown
- 2010-03-17 BR BRPI1013618A patent/BRPI1013618A2/pt not_active Application Discontinuation
- 2010-03-17 EP EP10709212.4A patent/EP2408752B1/en active Active
- 2010-03-17 MX MX2011009780A patent/MX2011009780A/es not_active Application Discontinuation
-
2011
- 2011-08-16 ZA ZA2011/05986A patent/ZA201105986B/en unknown
- 2011-08-18 IL IL214746A patent/IL214746A0/en unknown
- 2011-09-15 CL CL2011002300A patent/CL2011002300A1/es unknown
-
2013
- 2013-10-23 US US14/060,859 patent/US20140051674A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201101330A1 (ru) | 2012-04-30 |
| US20140051674A1 (en) | 2014-02-20 |
| ZA201105986B (en) | 2012-08-29 |
| UY32494A (es) | 2010-10-29 |
| JP5628281B2 (ja) | 2014-11-19 |
| MX2011009780A (es) | 2011-09-30 |
| AU2010224881A1 (en) | 2011-09-08 |
| US20110071158A1 (en) | 2011-03-24 |
| KR20110128927A (ko) | 2011-11-30 |
| CA2755759A1 (en) | 2010-09-23 |
| EP2408752A1 (en) | 2012-01-25 |
| WO2010106097A1 (en) | 2010-09-23 |
| CL2011002300A1 (es) | 2012-01-20 |
| EP2408752B1 (en) | 2015-08-12 |
| TW201043611A (en) | 2010-12-16 |
| AR076134A1 (es) | 2011-05-18 |
| IL214746A0 (en) | 2011-11-30 |
| JP2012520850A (ja) | 2012-09-10 |
| CN102421762A (zh) | 2012-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| BR112014028424A2 (pt) | compostos de pirimidina para o tratamento de câncer | |
| IL226326A0 (en) | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof | |
| BRPI1015215A2 (pt) | porções de ligação alvo armadas com amatoxina para o tratamento de câncer | |
| BRPI1010874A2 (pt) | composição para o tratamento de câncer de próstata | |
| BR112012011570A2 (pt) | aparelho para tratamento de fluido com radiação de microondas | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| PT2456889E (pt) | Marcadores para o cancro do endométrio | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI1006438A2 (pt) | terapia adjuvante de cancer | |
| HUE046667T2 (hu) | Rák kombinatív kezelése | |
| LT2707030T (lt) | Vėžio gydymas | |
| BRPI1006075A2 (pt) | biomarcadores de cancer | |
| BRPI1009919A2 (pt) | combinações de pentamidina para tratamento de câncer. | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| PT2340042E (pt) | Métodos e composições para o tratamento de cancro | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| PT2632452T (pt) | Compostos e composições para o tratamento do cancro | |
| BRPI0909016A2 (pt) | anticorpos úteis para o tratamento do câncer | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
| BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |